Latest net tangible assets for USRM: $-15M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
U.S. Stem Cell (USRM) currently reports a net tangible assets of $-15M as of December 2022. That compares with $-13M in the prior-year period — down 15.5% year over year. Use the charts on this page to explore U.S. Stem Cell's net tangible assets history and peer comparisons.
U.S. Stem Cell's net tangible assets decreased from $-13M to $-15M — a 15.5% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
U.S. Stem Cell reported $-15M in net tangible assets as of December 2022. That compares with $-13M in the prior-year period — down 15.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net tangible assets of $-15M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for U.S. Stem Cell, and consider following USRM for alerts when major investors trade the stock.
U.S. Stem Cell is classified in the Healthcare sector. On net tangible assets, it currently shows $-15M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing USRM with unrelated industries.